{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T16:08:18Z","timestamp":1744301298229},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T00:00:00Z","timestamp":1381968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s11239-013-1004-y","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T12:12:43Z","timestamp":1381925563000},"page":"235-240","source":"Crossref","is-referenced-by-count":6,"title":["Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers"],"prefix":"10.1007","volume":"38","author":[{"given":"Michael P.","family":"Ero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel R.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack L.","family":"Harbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Janc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay H.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Barriere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,17]]},"reference":[{"key":"1004_CR1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","volume":"49","author":"JP Shaw","year":"2005","unstructured":"Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S (2005) Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 49:195\u2013201. doi: 10.1128\/AAC.49.1.195-201.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"1004_CR2","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/429914","volume":"40","author":"ME Stryjewski","year":"2005","unstructured":"Stryjewski ME, O\u2019Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG Jr, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR (2005) Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 40:1601\u20131607. doi: 10.1086\/429914","journal-title":"Clin Infect Dis"},{"key":"1004_CR3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","volume":"50","author":"ME Stryjewski","year":"2006","unstructured":"Stryjewski ME, Chu VH, O\u2019Riordan WD, Warren BL, Dunbar LM, Young DM, Vallee M, Fowler VG Jr, Morganroth J, Barriere SL, Kitt MM, Corey GR (2006) Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50:862\u2013867. doi: 10.1128\/AAC.50.3.862-867.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"1004_CR4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","volume":"46","author":"ME Stryjewski","year":"2008","unstructured":"Stryjewski ME, Graham DR, Wilson SE, O\u2019Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR (2008) Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 46:1683\u20131693. doi: 10.1086\/587896","journal-title":"Clin Infect Dis"},{"key":"1004_CR5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1742-1241.2011.02668.x","volume":"65","author":"SL Barriere","year":"2011","unstructured":"Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM (2011) Effects of telavancin on coagulation test results. Int J Clin Pract 65:784\u2013789. doi: 10.1111\/j.1742-1241.2011.02668.x","journal-title":"Int J Clin Pract"},{"key":"1004_CR6","unstructured":"U.S. Food and Drug Administration (2009) Clinical Laboratory Improvement Amendments (CLIA). http:\/\/www.fda.gov\/medicaldevices\/deviceregulationandguidance\/ivdregulatoryassistance\/ucm124105.htm . Accessed 24 April 2013"},{"key":"1004_CR7","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1309\/AJCPDPL4G7CERYJU","volume":"136","author":"R Gosselin","year":"2011","unstructured":"Gosselin R, Dager W, Roberts A, Freeman L, Gandy L, Gregg J, Dwyre D (2011) Effect of telavancin (Vibativ) on routine coagulation test results. Am J Clin Pathol 136:848\u2013854. doi: 10.1309\/AJCPDPL4G7CERYJU","journal-title":"Am J Clin Pathol"},{"key":"1004_CR8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s11999-012-2612-0","volume":"471","author":"DF Amanatullah","year":"2013","unstructured":"Amanatullah DF, Lopez MJ, Gosselin RC, Gupta MC (2013) Case report: artificial elevation of prothrombin time by telavancin. Clin Orthop Relat Res 471:332\u2013335. doi: 10.1007\/s11999-012-2612-0","journal-title":"Clin Orthop Relat Res"},{"key":"1004_CR9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MBC.0b013e3282f10275","volume":"19","author":"PS Webster","year":"2008","unstructured":"Webster PS, Oleson FB Jr, Paterson DL, Arkin CF, Mangili A, Craven DE, Adcock DM, Lindfield KC, Knapp AG, Martone WJ (2008) Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time\/International Normalized Ratio results. Blood Coagul Fibrinolysis 19:32\u201338. doi: 10.1097\/MBC.0b013e3282f10275","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-013-1004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-013-1004-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-013-1004-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:02:03Z","timestamp":1559386923000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-013-1004-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,17]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1007\/s11239-013-1004-y","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,17]]}}}